Michael S. Piepenbrink

This study shows that mice vaccinated with a single-cycle influenza virus or a neuraminidase-decorated nanoparticle are protected from lethal H5N1 influenza challenge.

This study shows that a combination of antibodies targeting both the SARS-CoV-2 spike protein's receptor binding domain (RBD) and stem helix (SH) domains prevents the emergence of viral escape mutants.

This study characterizes a broad-neutralizing influenza antibody, 1122A11, showing it neutralizes multiple NA subtypes and adapts to recent glycosylation changes in H3N2 viruses.

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.